SG194922A1 - Dry-coated tablet containing tegafur, gimeracil and oteracil potassium - Google Patents
Dry-coated tablet containing tegafur, gimeracil and oteracil potassium Download PDFInfo
- Publication number
- SG194922A1 SG194922A1 SG2013083829A SG2013083829A SG194922A1 SG 194922 A1 SG194922 A1 SG 194922A1 SG 2013083829 A SG2013083829 A SG 2013083829A SG 2013083829 A SG2013083829 A SG 2013083829A SG 194922 A1 SG194922 A1 SG 194922A1
- Authority
- SG
- Singapore
- Prior art keywords
- dry
- coated tablet
- outer shell
- mass
- tablet
- Prior art date
Links
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title claims abstract description 45
- 229960001674 tegafur Drugs 0.000 title claims abstract description 45
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 title claims abstract description 39
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 229950009822 gimeracil Drugs 0.000 title claims abstract description 39
- 229950000193 oteracil Drugs 0.000 title claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- 238000012360 testing method Methods 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 29
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 25
- 229920002678 cellulose Polymers 0.000 claims description 25
- 239000001913 cellulose Substances 0.000 claims description 25
- 239000008101 lactose Substances 0.000 claims description 25
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 22
- 229960000913 crospovidone Drugs 0.000 claims description 22
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 22
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 22
- 229920000881 Modified starch Polymers 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 19
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 15
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 15
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 15
- 239000007884 disintegrant Substances 0.000 claims description 13
- 238000012812 general test Methods 0.000 claims description 13
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 7
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 7
- 229950008138 carmellose Drugs 0.000 claims description 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 229940099112 cornstarch Drugs 0.000 claims description 3
- 239000003826 tablet Substances 0.000 description 177
- 239000008358 core component Substances 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 230000009467 reduction Effects 0.000 description 12
- 239000000306 component Substances 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- 238000007922 dissolution test Methods 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 239000000654 additive Substances 0.000 description 8
- 239000006191 orally-disintegrating tablet Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 102100036360 Cadherin-3 Human genes 0.000 description 5
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 229940000425 combination drug Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000000748 compression moulding Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000000989 food dye Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 229920003115 HPC-SL Polymers 0.000 description 1
- 229920003116 HPC-SSL Polymers 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- -1 sucrose fatty acid ester Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011116884 | 2011-05-25 | ||
| PCT/JP2012/063260 WO2012161240A1 (ja) | 2011-05-25 | 2012-05-24 | テガフール、ギメラシル、オテラシルカリウム含有有核錠 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG194922A1 true SG194922A1 (en) | 2013-12-30 |
Family
ID=47217314
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013083829A SG194922A1 (en) | 2011-05-25 | 2012-05-24 | Dry-coated tablet containing tegafur, gimeracil and oteracil potassium |
| SG10201505503WA SG10201505503WA (en) | 2011-05-25 | 2012-05-24 | Dry-coated tablet containing tegafur, gimeracil and oteracil potassium |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201505503WA SG10201505503WA (en) | 2011-05-25 | 2012-05-24 | Dry-coated tablet containing tegafur, gimeracil and oteracil potassium |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140335174A1 (enExample) |
| EP (1) | EP2716290B1 (enExample) |
| JP (2) | JP5689173B2 (enExample) |
| KR (2) | KR101869127B1 (enExample) |
| AU (1) | AU2012259803B2 (enExample) |
| BR (1) | BR112013030093B1 (enExample) |
| CA (1) | CA2836865C (enExample) |
| ES (1) | ES2671926T3 (enExample) |
| IL (1) | IL229372B (enExample) |
| MX (1) | MX353289B (enExample) |
| MY (1) | MY167883A (enExample) |
| PH (1) | PH12013502323A1 (enExample) |
| RU (1) | RU2601620C2 (enExample) |
| SG (2) | SG194922A1 (enExample) |
| TW (2) | TWI488659B (enExample) |
| WO (1) | WO2012161240A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013030093B1 (pt) * | 2011-05-25 | 2019-12-10 | Taiho Pharmaceutical Co Ltd | comprimido revestido seco de desintegração oral contendo tegafur, gimeracilo e oteracilo potássico |
| CN107837273A (zh) * | 2016-09-18 | 2018-03-27 | 江苏金甙生物技术有限公司 | 一种肠溶替吉奥缓释制剂及其制备方法 |
| CN107865871B (zh) * | 2016-09-23 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种替吉奥组合物及其制备方法 |
| CN106619689B (zh) * | 2016-12-30 | 2018-05-01 | 陈晓华 | 一种用于治疗癌症的药物组合物、试剂盒及其应用 |
| US20220408745A1 (en) * | 2019-09-13 | 2022-12-29 | Meiji Co., Ltd. | Solid food and solid milk having hole penetrating first face and second face |
| CN119365195A (zh) * | 2022-06-10 | 2025-01-24 | 大鹏药品工业株式会社 | 含有匹米替比的医药组合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0148589B1 (ko) * | 1991-05-27 | 1998-11-02 | 고바야시 유끼오 | 항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트 |
| DE69901938T3 (de) * | 1998-03-06 | 2012-08-02 | Aptalis Pharma S.R.L. | Schnell zerfallende tablette |
| ES2257412T3 (es) * | 2000-05-18 | 2006-08-01 | Therics, Inc. | Encapsulacion de un nucleo toxico en una region no toxica en una forma de dosificacion oral. |
| CN1284532C (zh) * | 2001-09-28 | 2006-11-15 | 株式会社三和化学研究所 | 有核型速溶崩解性成型品 |
| DK1443917T3 (da) * | 2001-11-07 | 2006-07-17 | Synthon Bv | Tamsulosintabletter |
| US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| US20030215502A1 (en) * | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
| MXPA05009781A (es) * | 2003-03-14 | 2005-10-26 | Taiho Pharmaceutical Co Ltd | Potenciador de efecto antitumoral y agente antitumoral. |
| EP1680092A2 (en) * | 2003-09-29 | 2006-07-19 | Cipla Ltd. | Pharmaceutical formulation with improved stability |
| CN100333726C (zh) | 2004-12-23 | 2007-08-29 | 鲁南制药集团股份有限公司 | 含有替加氟、吉莫斯特和氧嗪酸钾的口腔崩解片 |
| EP1864683B1 (en) * | 2005-04-01 | 2010-09-01 | Taiho Pharmaceutical Co., Ltd. | Radiotherapy enhancer |
| JP4994618B2 (ja) * | 2005-08-11 | 2012-08-08 | 学校法人北里研究所 | Ｔｓ−１／カンプトテシン類による化学放射線療法 |
| CN101909602B (zh) * | 2007-12-27 | 2012-06-13 | 大鹏药品工业株式会社 | 口服粉粒状抗肿瘤剂 |
| TWI468188B (zh) * | 2008-01-30 | 2015-01-11 | Univ Tokushima | Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation |
| KR100934876B1 (ko) | 2008-01-31 | 2010-01-06 | 성균관대학교산학협력단 | Ｌｉｇａ공정의 도금방법 |
| CN101380327B (zh) * | 2008-10-09 | 2011-01-26 | 北京恒瑞康达医药科技发展有限公司 | 抗癌复合缓释组合物及制备 |
| JP5553522B2 (ja) | 2009-03-31 | 2014-07-16 | 大鵬薬品工業株式会社 | 経口投与用医薬組成物 |
| JPWO2010131460A1 (ja) * | 2009-05-12 | 2012-11-01 | 大鵬薬品工業株式会社 | テガフール・ギメラシル・オテラシルカリウム配合剤及びオキサリプラチンを含有する抗腫瘍剤 |
| CN101711765B (zh) * | 2009-10-31 | 2011-03-23 | 山东新时代药业有限公司 | 一种含有替加氟、吉美嘧啶和奥替拉西钾的分散片 |
| BR112013030093B1 (pt) * | 2011-05-25 | 2019-12-10 | Taiho Pharmaceutical Co Ltd | comprimido revestido seco de desintegração oral contendo tegafur, gimeracilo e oteracilo potássico |
| CN102614183B (zh) * | 2012-03-05 | 2013-10-30 | 齐鲁制药(海南)有限公司 | 一种替吉奥的口服制剂 |
-
2012
- 2012-05-24 BR BR112013030093A patent/BR112013030093B1/pt not_active IP Right Cessation
- 2012-05-24 CA CA2836865A patent/CA2836865C/en not_active Expired - Fee Related
- 2012-05-24 KR KR1020137033946A patent/KR101869127B1/ko not_active Expired - Fee Related
- 2012-05-24 KR KR1020177016653A patent/KR20170072959A/ko not_active Ceased
- 2012-05-24 EP EP12789023.4A patent/EP2716290B1/en not_active Not-in-force
- 2012-05-24 US US14/118,952 patent/US20140335174A1/en not_active Abandoned
- 2012-05-24 SG SG2013083829A patent/SG194922A1/en unknown
- 2012-05-24 JP JP2013516428A patent/JP5689173B2/ja active Active
- 2012-05-24 ES ES12789023.4T patent/ES2671926T3/es active Active
- 2012-05-24 MX MX2013013563A patent/MX353289B/es active IP Right Grant
- 2012-05-24 WO PCT/JP2012/063260 patent/WO2012161240A1/ja not_active Ceased
- 2012-05-24 MY MYPI2013702158A patent/MY167883A/en unknown
- 2012-05-24 SG SG10201505503WA patent/SG10201505503WA/en unknown
- 2012-05-24 PH PH1/2013/502323A patent/PH12013502323A1/en unknown
- 2012-05-24 TW TW101118538A patent/TWI488659B/zh not_active IP Right Cessation
- 2012-05-24 AU AU2012259803A patent/AU2012259803B2/en not_active Ceased
- 2012-05-24 RU RU2013157528/15A patent/RU2601620C2/ru active
- 2012-05-24 TW TW104113084A patent/TWI566787B/zh not_active IP Right Cessation
-
2013
- 2013-11-11 IL IL229372A patent/IL229372B/en active IP Right Grant
-
2014
- 2014-08-20 JP JP2014167814A patent/JP5769853B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MY167883A (en) | 2018-09-26 |
| IL229372B (en) | 2018-12-31 |
| KR20140037879A (ko) | 2014-03-27 |
| KR20170072959A (ko) | 2017-06-27 |
| TW201300141A (zh) | 2013-01-01 |
| AU2012259803B2 (en) | 2016-03-17 |
| SG10201505503WA (en) | 2015-09-29 |
| TW201529100A (zh) | 2015-08-01 |
| RU2013157528A (ru) | 2015-06-27 |
| CA2836865A1 (en) | 2012-11-29 |
| BR112013030093A2 (pt) | 2016-09-20 |
| RU2601620C2 (ru) | 2016-11-10 |
| EP2716290A1 (en) | 2014-04-09 |
| US20140335174A1 (en) | 2014-11-13 |
| JP5769853B2 (ja) | 2015-08-26 |
| EP2716290B1 (en) | 2018-03-14 |
| IL229372A0 (en) | 2014-01-30 |
| PH12013502323A1 (en) | 2014-01-06 |
| MX2013013563A (es) | 2013-12-16 |
| KR101869127B1 (ko) | 2018-06-19 |
| WO2012161240A1 (ja) | 2012-11-29 |
| TWI488659B (zh) | 2015-06-21 |
| JPWO2012161240A1 (ja) | 2014-07-31 |
| JP2014218523A (ja) | 2014-11-20 |
| TWI566787B (zh) | 2017-01-21 |
| MX353289B (es) | 2018-01-05 |
| CA2836865C (en) | 2018-02-27 |
| NZ617625A (en) | 2015-10-30 |
| JP5689173B2 (ja) | 2015-03-25 |
| ES2671926T3 (es) | 2018-06-11 |
| EP2716290A4 (en) | 2014-11-26 |
| BR112013030093B1 (pt) | 2019-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9820983B2 (en) | Immediate release pharmaceutical compositions comprising oxycodone and naloxone | |
| CA2836865C (en) | Dry-coated tablet containing tegafur, gimeracil and oteracil potassium | |
| US20170014340A1 (en) | Orally Disintegrating Tablet of Nabilone Comprising Mannitol-Based Granules | |
| EP2612657B1 (en) | Orodispersible tablet | |
| CN102895212B (zh) | 含有替加氟、吉美拉西、氧嗪酸钾的干压包衣片 | |
| NZ617625B2 (en) | Dry-coated tablet containing tegafur, gimeracil and oteracil potassium | |
| JP2019210262A (ja) | 口腔内崩壊錠剤 | |
| HK1180584B (en) | Dry pressure coated tablet containing tegafur, gimeracil, oteracil potassium | |
| JP2016183195A (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |